3 comments By Media Staff   |  Thursday, February 14, 2013 Researchers have found that the investigational drug selumetinib shuts down the signaling of genetic mutations that prevent some patients’ thyroid cancer tumors from absorbing radioiodine, the most effective treatment for the disease. read more

Originally posted here:
Drug Reverses Radioiodine Resistance in Some People with Advanced Thyroid Cancer

Scroll to Top